Vertex (VRTX) Q4 2025 earnings review
Diversification Takes Root: Non-CF Revenue Set to Triple
Vertex delivered a clean Q4 beat with 10% revenue growth, but the real story is the successful pivot from a single-disease company to a diversified biopharma major. While the Cystic Fibrosis (CF) juggernaut continues to churn out cash ($12B FY revenue), the launch products—CASGEVY (gene editing) and JOURNAVX (pain)—are hitting an inflection point. Management's FY26 guidance projects Non-CF revenue to exceed $500M, a massive acceleration from ~$176M in FY25. With a $12.3B cash fortress and a rolling BLA for Povetacicept in IgAN, the growth engine is firing on multiple cylinders.
🐂 Bull Case
The 'Non-CF' segment is no longer a rounding error. Guidance for FY26 calls for >$500M in revenue from CASGEVY and JOURNAVX, implying a near-tripling of this segment YoY. CASGEVY Q4 revenue ($54M) alone exceeded the entire H1 2025 total.
Vertex is not resting on approvals. The company initiated a rolling BLA for Povetacicept (IgAN) and expects a potential approval in 2026. Combined with Inaxaplin (AMKD) and Suzetrigine (DPN), three potential blockbusters are in late-stage development.
🐻 Bear Case
Diversification is expensive. GAAP OpEx is guided to ~$6.4B in FY26. While necessary for launches, this heavy spend suppresses near-term operating leverage even as revenue scales.
The days of single-digit or low-double-digit tax rates are fading. FY26 tax guidance is 19.5-20.5%, significantly higher than the 10.5% GAAP rate seen in Q4, creating a mechanical drag on EPS growth.
⚖️ Verdict: 🟢🟢
Strong Buy. Vertex is executing a rare feat in biotech: using a cash-cow monopoly (CF) to successfully fund and launch entirely new franchises (Pain, Blood Disorders, Renal). The FY26 guidance confirms the diversification thesis is working.
Key Themes
The Non-CF Breakout
FY26 guidance explicitly targets $500M+ in Non-CF revenue. This is a critical threshold that validates the multi-billion dollar investments in gene therapy and pain. Q4 saw CASGEVY revenue hit $54M (vs $2M in 24Q4) and JOURNAVX hit $27M (launch phase). The trajectory suggests exponential rather than linear growth for these assets.
CF Franchise Durability: The ALYFTREK Upgrade
The CF business isn't just stable; it's evolving. ALYFTREK generated $380M in Q4 (up from $247M in Q3), rapidly cannibalizing older drugs. This is positive: ALYFTREK extends IP protection into the late 2030s and offers better economics. Total CF revenue grew ~8% YoY in Q4, proving the mature franchise still has pricing and patient expansion power.
Renal Franchise Emerges
Vertex is effectively building a renal vertical. The rolling BLA submission for Povetacicept in IgA Nephropathy (IgAN) has begun. With Inaxaplin (AMKD) advancing, Vertex is positioning to dominate niche renal indications similar to its CF playbook.
Gross Margin Pressure
While still elite, GAAP Gross Margin compressed slightly to 85.4% in 25Q4 from 86.5% in 25Q3. As the mix shifts toward CASGEVY (a complex cell therapy with higher manufacturing costs) and away from small molecules, blended gross margins may face structural headwinds compared to the pure-CF era.
Cash Fortress & Allocation
Ending the year with $12.3B in cash despite heavy R&D spend and share repurchases gives Vertex immense optionality. The guidance includes ~$100M for AIPR&D, signaling continued appetite for 'bolt-on' deals to feed the pipeline.
Other KPIs
Accelerating. Up significantly from $16.9M in Q3 and $2M a year ago. 64 patients infused in FY25 (30 in Q4 alone). The complex logistics chain is smoothing out, leading to faster revenue recognition.
Early Launch. Up from $19.6M in Q3. With >550k prescriptions written since launch, the volume is high, but revenue lags due to payer coverage ramp-up and stocking dynamics. FY26 will be the true test of commercial conversion.
Operating cash flow remains robust, funding the entire $5.8B R&D budget (GAAP) with ease. The business model is self-funding high-risk innovation.
Guidance
Stable. Implies ~8.5% YoY growth at the midpoint, consistent with the 9% growth delivered in FY25. The growth engine is shifting from pure CF volume to a mix of CF pricing/stability and Non-CF expansion.
Accelerating. Represents a massive jump from ~$176M in FY25. This is the key metric for investors tracking the 'Vertex 2.0' thesis.
Accelerating. Up ~11% from FY25 Non-GAAP OpEx of $5.1B. Management is aggressively reinvesting revenue gains into the commercial launches and the renal pipeline.
Decelerating (Headwind). A step up from the ~17% Non-GAAP rate in FY25, creating a drag on bottom-line growth relative to the top line.
Key Questions
Non-CF Split
Of the projected $500M+ in Non-CF revenue, what is the assumed split between CASGEVY and JOURNAVX, and does this guidance assume any specific payer coverage milestones for JOURNAVX?
VX-522 Update
Can you provide more granularity on the status of the VX-522 (mRNA) program following the 'tolerability issue' mentioned earlier in 2025? When will we see pivotal data for the final 5% of CF patients?
Gross Margin Evolution
With CASGEVY scaling to hundreds of millions in revenue, how should we model the long-term gross margin profile? Is the 86% range sustainable, or will cell therapy mix shift drag this down toward 80%?